Compound antibody, adding constant negative TB-1 (TBC1) or TBC2 receiver region. (Divisional request 201803096)

摘要

T. LT; P GT; Current invention; Oacute; N involves selectively binding to regional and provincial complex antibodies; Oacute; N constant TCR BETA 1 (TRBC1) or TRBC2, which are combined to use this antibody in the treatment of C AMP lymphoma or leukemia; EACUTE; Lulas T. Composici AMP; Oacute; ARMAC AMP; EACUTE; UTICA and M AMP; EACUTE; everything; / P GT;